Literature DB >> 34417329

PI3Kγ/AKT Signaling in High Molecular Weight Hyaluronan (HMWH)-Induced Anti-Hyperalgesia and Reversal of Nociceptor Sensitization.

Ivan J M Bonet1, Eugen V Khomula1, Dionéia Araldi1, Paul G Green2, Jon D Levine3.   

Abstract

High molecular weight hyaluronan (HMWH), a well-established treatment for osteoarthritis pain, is anti-hyperalgesic in preclinical models of inflammatory and neuropathic pain. HMWH-induced anti-hyperalgesia is mediated by its action at cluster of differentiation 44 (CD44), the cognate hyaluronan receptor, which can signal via phosphoinositide 3-kinase (PI3K), a large family of kinases involved in diverse cell functions. We demonstrate that intrathecal administration of an oligodeoxynucleotide (ODN) antisense to mRNA for PI3Kγ (a Class I PI3K isoform) expressed in dorsal root ganglia (DRGs), and intradermal administration of a PI3Kγ-selective inhibitor (AS605240), markedly attenuates HMWH-induced anti-prostaglandin E2 (PGE2) hyperalgesia, in male and female rats. Intradermal administration of inhibitors of mammalian target of rapamycin (mTOR; rapamycin) and protein kinase B (AKT; AKT Inhibitor IV), signaling molecules downstream of PI3Kγ, also attenuates HMWH-induced anti-hyperalgesia. In vitro patch-clamp electrophysiology experiments on cultured nociceptors from male rats demonstrate that some HMWH-induced changes in generation of action potentials (APs) in nociceptors sensitized by PGE2 are PI3Kγ dependent (reduction in AP firing rate, increase in latency to first AP and increase in slope of current ramp required to induce AP) and some are PI3Kγ independent [reduction in recovery rate of AP afterhyperpolarization (AHP)]. Our demonstration of a role of PI3Kγ in HMWH-induced anti-hyperalgesia and reversal of nociceptor sensitization opens a novel line of research into molecular targets for the treatment of diverse pain syndromes.SIGNIFICANCE STATEMENT We have previously demonstrated that high molecular weight hyaluronan (HMWH) attenuates inflammatory hyperalgesia, an effect mediated by its action at cluster of differentiation 44 (CD44), the cognate hyaluronan receptor, and activation of its downstream signaling pathway, in nociceptors. In the present study, we demonstrate that phosphoinositide 3-kinase (PI3K)γ and downstream signaling pathway, protein kinase B (AKT) and mammalian target of rapamycin (mTOR), are crucial for HMWH to induce anti-hyperalgesia.
Copyright © 2021 the authors.

Entities:  

Keywords:  anti-hyperalgesia; electrical excitability; high molecular weight hyaluronan; hyperalgesia; phosphoinositide 3-kinases

Mesh:

Substances:

Year:  2021        PMID: 34417329      PMCID: PMC8496198          DOI: 10.1523/JNEUROSCI.1189-21.2021

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  98 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  Differential distribution of PI3K isoforms in spinal cord and dorsal root ganglia: potential roles in acute inflammatory pain.

Authors:  Mathias Leinders; Fred J Koehrn; Beatrix Bartok; David L Boyle; Veronica Shubayev; Iveta Kalcheva; Nam-Kyung Yu; Jihye Park; Bong-Kiun Kaang; Michael P Hefferan; Gary S Firestein; Linda S Sorkin
Journal:  Pain       Date:  2014-03-12       Impact factor: 6.961

3.  Light scattering and birefringence changes during nerve activity.

Authors:  L B Cohen; R D Keynes; B Hille
Journal:  Nature       Date:  1968-05-04       Impact factor: 49.962

Review 4.  Measuring nerve excitation with polarized light.

Authors:  D Landowne
Journal:  Jpn J Physiol       Date:  1993

5.  The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation.

Authors:  C A Cuff; D Kothapalli; I Azonobi; S Chun; Y Zhang; R Belkin; C Yeh; A Secreto; R K Assoian; D J Rader; E Puré
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Phosphatidylinositol 3-kinase is a key mediator of central sensitization in painful inflammatory conditions.

Authors:  Sophie Pezet; Fabien Marchand; Richard D'Mello; John Grist; Anna K Clark; Marzia Malcangio; Anthony H Dickenson; Robert J Williams; Stephen B McMahon
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

Review 7.  Metabolic control of hyaluronan synthases.

Authors:  Davide Vigetti; Manuela Viola; Evgenia Karousou; Giancarlo De Luca; Alberto Passi
Journal:  Matrix Biol       Date:  2013-10-14       Impact factor: 11.583

8.  The neural coding of stimulus intensity: linking the population response of mechanoreceptive afferents with psychophysical behavior.

Authors:  Michael A Muniak; Supratim Ray; Steven S Hsiao; J Frank Dammann; Sliman J Bensmaia
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

9.  Hyperalgesic priming (type II) induced by repeated opioid exposure: maintenance mechanisms.

Authors:  Dioneia Araldi; Luiz F Ferrari; Jon D Levine
Journal:  Pain       Date:  2017-07       Impact factor: 7.926

10.  Upregulation of T-type Ca2+ channels in long-term diabetes determines increased excitability of a specific type of capsaicin-insensitive DRG neurons.

Authors:  Dmytro E Duzhyy; Viacheslav Y Viatchenko-Karpinski; Eugen V Khomula; Nana V Voitenko; Pavel V Belan
Journal:  Mol Pain       Date:  2015-05-20       Impact factor: 3.395

View more
  2 in total

1.  Second messengers mediating high-molecular-weight hyaluronan-induced antihyperalgesia in rats with chemotherapy-induced peripheral neuropathy.

Authors:  Ivan J M Bonet; Larissa Staurengo-Ferrari; Dionéia Araldi; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2021-12-06       Impact factor: 7.926

Review 2.  Action of Hyaluronic Acid as a Damage-Associated Molecular Pattern Molecule and Its Function on the Treatment of Temporomandibular Disorders.

Authors:  Natália Dos Reis Ferreira; Carolina Kaminski Sanz; Aline Raybolt; Cláudia Maria Pereira; Marcos Fabio DosSantos
Journal:  Front Pain Res (Lausanne)       Date:  2022-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.